Axillary hyperhidrosis, a medical condition characterized by excessive sweating in the armpit area, affects a significant portion of the global population. This condition can have a profound impact on the quality of life, causing discomfort, embarrassment, and social withdrawal. As awareness of axillary hyperhidrosis increases, the demand for effective treatment options is growing, driving theContinue reading “Axillary Hyperhidrosis Market: Growth Prospects and Size Projection”
Category Archives: Business Consulting
Healthcare Consulting Services: Enabling Transformation in the Healthcare Industry
The healthcare industry is experiencing tremendous challenges due to the constantly evolving regulatory environment, advancing technology, and rising patient expectations. In this dynamic landscape, healthcare providers are turning to healthcare consulting services to navigate through the complexities and optimize their operations. Healthcare consulting services offer expertise, strategic planning, and actionable recommendations to help organizations improveContinue reading “Healthcare Consulting Services: Enabling Transformation in the Healthcare Industry”
The Growing Landscape of the Attention Deficit Hyperactivity Disorder Market
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that affects millions of people worldwide, with a significant impact on their daily lives. While the exact causes of Attention Deficit Hyperactivity Disorder remain unclear, it is widely recognized as a condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity. As awareness and diagnosis ofContinue reading “The Growing Landscape of the Attention Deficit Hyperactivity Disorder Market”
Consistent Results Across All Sub-Groups Seen in the Newly Launched First in Class LAG-3 Combination Drug Opdualag
LAG-3 combination drug Opdualag: ASCO 2022 Bristol Myers Squibb presented a subgroup analysis from the RELATIVITY-047 trial for the newly approved OPDUALAG for the unresectable or metastatic melanoma patients. Nivolumab Mechanism of Action: Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants Recently, FDA approved Opdualag, a fixed-dose combination of nivolumabContinue reading “Consistent Results Across All Sub-Groups Seen in the Newly Launched First in Class LAG-3 Combination Drug Opdualag”
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022
ASCO 2022: Teclistamab for Multiple Myeloma Latest teclistamab findings presented at the ASCO 2022 Annual Meeting demonstrate a profound and long-lasting response (Abstract # 8007, 8013, and 8032) Mechanism of Action: Bispecific IgG4 antibody that binds BCMA and CD3 to redirect T-cells to multiple myeloma cells Teclistamab is a bispecific antibody that targets BCMA [B-cell maturation agent]Continue reading “Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022”
Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC trial
In the Phase Ib/II clinical trial of Sabizabulin in men with metastatic castration-resistant prostate cancer, Veru published important findings. Sabizabulin Mechanism of Action: Tubulin inhibitors; Tubulin polymerization inhibitors The alpha and beta-tubulin subunits of cellular intermediate filaments and microtubules are targeted, bound, and crosslinked by the first-in-class small chemical sabizabulin, disrupting the cytoskeleton. Additionally, sabizabulinContinue reading “Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC trial”
Trodelvy met the primary endpoint in the TROPiCS02 study in extensively pretreated HR+/HER2 breast cancer patients
In a Phase III trial, Gilead Sciences’ Trodelvy met the primary endpoints, lowering the probability of disease progression or death by 30%. In TROPiCS-02, Trodelvy was compared to chemotherapy in third-line HER2+, ER+ breast cancer. The anti-Trop-2 antibody-drug conjugate (ADC), which is already approved for third-line or later triple-negative breast cancer and post-chemo/PD-(L) 1 urothelialContinue reading “Trodelvy met the primary endpoint in the TROPiCS02 study in extensively pretreated HR+/HER2 breast cancer patients”
A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022
Diffuse Large B Cell Lymphoma is a deadly blood cancer that is the most frequent kind of non-Hodgkin lymphoma (NHL), with over 40,000 new cases diagnosed in Europe each year and another 25,000 in the United States. While the ASCO 2022 annual meeting is approaching, pharma behemoths such as Seagen, Hoffmann-La Roche, and others areContinue reading “A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022”
What is the Leber Congenital Amaurosis Market Size?
DelveInsight’s “Leber Congenital Amaurosis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Leber Congenital Amaurosis, historical and forecasted epidemiology as well as the Leber Congenital Amaurosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Leber Congenital Amaurosis market report provides currentContinue reading “What is the Leber Congenital Amaurosis Market Size?”
What is the Gastrointestinal Stromal Tumor Market Research?
DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Gastrointestinal Stromal Tumor (GIST), historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Gastrointestinal Stromal Tumor market report providesContinue reading “What is the Gastrointestinal Stromal Tumor Market Research?”
DelveInsight 